Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Shares Issued (2019 - 2025)

Keros Therapeutics' Shares Issued history spans 7 years, with the latest figure at $117000.0 for Q3 2025.

  • For Q3 2025, Shares Issued rose 101.35% year-over-year to $117000.0; the TTM value through Dec 2025 reached $138000.0, down 98.86%, while the annual FY2025 figure was $138000.0, 98.86% down from the prior year.
  • Shares Issued reached $117000.0 in Q3 2025 per KROS's latest filing, up from $17000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $48.5 million in Q3 2022 to a low of -$57.4 million in Q4 2022.
  • Average Shares Issued over 5 years is $879000.0, with a median of $311000.0 recorded in 2023.
  • The largest YoY upside for Shares Issued was 49076.77% in 2022 against a maximum downside of 15234.3% in 2022.
  • A 5-year view of Shares Issued shows it stood at $379000.0 in 2021, then crashed by 15234.3% to -$57.4 million in 2022, then soared by 101.4% to $804000.0 in 2023, then surged by 1410.07% to $12.1 million in 2024, then tumbled by 99.04% to $117000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Shares Issued are $117000.0 (Q3 2025), $17000.0 (Q2 2025), and $4000.0 (Q1 2025).